Researcher

Qi-Jing Li is a Distinguished Principal Scientist at the Institute of Molecular and Cell Biology (IMCB) and Singapore Immunology Network (SIgN). He holds a B.S. in Biochemistry and Molecular Biology from Peking University. During his PhD studies at UC Riverside, mentored by Manuela Martins-Green, he focused on chemokine gene regulation in wound healing. As a Helen Hay Whitney Postdoctoral Fellow under Mark Davis at Stanford University, Li specialised in T cell biology, making key discoveries in T cell receptor activation and the role of microRNA in immunology. At Duke University School of Medicine, he established his lab to research tumour immunology and immunotherapies, translating his findings into clinical applications and co-founding three clinical-stage companies: HRain Biotech, TCRCure Biopharma and Hervor Therapeutics, which develop advanced cancer treatments.